AREC - Ticker AI Digest

Arecor Therapeutics PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (AREC) 1
AREC 06:01
Arecor Therapeutics PLC
Directorate Changes
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
AREC 06:01
Arecor Therapeutics PLC
Co-Development Agreement & Monetisation Deal
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Arecor Therapeutics plc, a biopharmaceutical company focused on diabetes and cardiometabolic diseases, announced two significant strategic developments on September 25, 2025
1. **Co-Development Agreement with Sequel Med Tech:**
Arecor has partnered with Sequel Med Tech, LLC, a US-based insulin pump device company, to co-develop AT278 (500U/mL), an ultra-concentrated and ultra-rapid acting insulin. The collaboration aims to integrate AT278 with Sequels twiistâ„¢ Automated Insulin Delivery (AID) system, powered by Tidepool. Both companies will jointly fund up to $1.3 million each for Phase 2 trial-enabling development work, including regulatory filings, manufacturing, and system compatibility. The goal is to achieve IND (Investigational New Drug) filing by 1H 2026 and initiate a pivotal Phase 2 trial in 2H 2026. The partnership also includes a broader co-development and commercialization agreement for future phases. This collaboration addresses unmet needs in diabetes management, particularly for patients requiring high daily insulin doses and extended-wear devices.
2. **Monetisation Deal with Ligand Pharmaceuticals:**
Arecor secured up to $11 million in non-dilutive funding by selling royalty rights related to AT220 (an Arestat®-enhanced biosimilar) and milestone/technology access fees for AT292 (now Sanofis Efdoralprin alfa) to Ligand Pharmaceuticals. The deal includes a $7 million upfront payment and $4 million in milestone payments, with $1 million expected in 2026. This funding extends Arecors cash runway to 1H 2027, enabling accelerated clinical development of AT278 without shareholder dilution.
**Key Highlights**
AT278 is positioned as the only ultra-concentrated, ultra-rapid insulin in development, designed for next-generation AID systems.
The Sequel partnership aligns with Arecors focus on transformative drug delivery solutions, leveraging Sequels advanced twiistâ„¢ system for precise insulin dosing.
The Ligand deal strengthens Arecors financial position, supporting R&D priorities like AT278 and oral peptide delivery platforms.
The total addressable US insulin market for AT278 is estimated at $2.9 billion, with additional global commercialization potential.
These agreements mark significant milestones for Arecor, enhancing its pipeline, financial stability, and market opportunities in diabetes care.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 1
AREC 06:01
Arecor Therapeutics PLC
Positive FDA Feedback on Phase 2 Study Design
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Arecor Therapeutics plc announced positive feedback from the U.S. Food and Drug Administration (FDA) on the Phase 2 clinical study design for its ultra-concentrated (500 U/mL) and ultra-rapid acting insulin, AT278, in combination with an Automated Insulin Delivery (AID) system. This first-of-its-kind study will evaluate AT278 in patients with type 1 and type 2 diabetes who have high daily insulin needs. Key highlights include
1. **Study Design Innovation**
Primary efficacy endpoint uses **Time-in-Range (TIR)**, enabling faster development compared to traditional HbA1c measurements.
Six-week dosing period for TIR vs. 12 weeks for HbA1c, accelerating clinical timelines.
Combination with an AID system to generate data on patient benefits and economic value.
2. **AT278’s Unique Features**
Only insulin in development with potential for longer wear in existing AID systems and future insulin pump miniaturization.
Ultra-concentrated and ultra-rapid profile addresses unmet needs in diabetes treatment.
3. **Phase 2 Study Details**
Planned IND submission to FDA in 2026, with study commencement in mid-2026, subject to funding.
Six-week cross-over study comparing AT278 (500 U/mL) with NovoLog® (100 U/mL) in <100 subjects.
Builds on positive Phase 1 data showing superiority over existing insulin products.
4. **Strategic Partnerships**
Arecor aims to partner with a U.S. insulin pump company for the Phase 2 study, advancing next-generation AID systems.
5. **CEO Commentary**
Sarah Howell highlighted the FDA feedback as a significant milestone, emphasizing AT278’s potential to simplify care and improve outcomes for diabetes patients.
Arecor is positioned to establish a new frontier in diabetes treatment, pending further financing and successful trial execution.
**END**
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 2
AREC 06:01
Arecor Therapeutics PLC
Interim results for the six months to 30 June 2025
AREC 08:31
Arecor Therapeutics PLC
Notice of Interim Results
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 5
AREC 06:01
Arecor Therapeutics PLC
Directorate Changes
AREC 06:01
Arecor Therapeutics PLC
Interim results for the six months to 30 June 2025
AREC 06:01
Arecor Therapeutics PLC
Co-Development Agreement & Monetisation Deal
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Arecor Therapeutics plc, a biopharmaceutical company focused on diabetes and cardiometabolic diseases, announced two significant strategic developments on September 25, 2025
1. **Co-Development Agreement with Sequel Med Tech:**
Arecor has partnered with Sequel Med Tech, LLC, a US-based insulin pump device company, to co-develop AT278 (500U/mL), an ultra-concentrated and ultra-rapid acting insulin. The collaboration aims to integrate AT278 with Sequels twiistâ„¢ Automated Insulin Delivery (AID) system, powered by Tidepool. Both companies will jointly fund up to $1.3 million each for Phase 2 trial-enabling development work, including regulatory filings, manufacturing, and system compatibility. The goal is to achieve IND (Investigational New Drug) filing by 1H 2026 and initiate a pivotal Phase 2 trial in 2H 2026. The partnership also includes a broader co-development and commercialization agreement for future phases. This collaboration addresses unmet needs in diabetes management, particularly for patients requiring high daily insulin doses and extended-wear devices.
2. **Monetisation Deal with Ligand Pharmaceuticals:**
Arecor secured up to $11 million in non-dilutive funding by selling royalty rights related to AT220 (an Arestat®-enhanced biosimilar) and milestone/technology access fees for AT292 (now Sanofis Efdoralprin alfa) to Ligand Pharmaceuticals. The deal includes a $7 million upfront payment and $4 million in milestone payments, with $1 million expected in 2026. This funding extends Arecors cash runway to 1H 2027, enabling accelerated clinical development of AT278 without shareholder dilution.
**Key Highlights**
AT278 is positioned as the only ultra-concentrated, ultra-rapid insulin in development, designed for next-generation AID systems.
The Sequel partnership aligns with Arecors focus on transformative drug delivery solutions, leveraging Sequels advanced twiistâ„¢ system for precise insulin dosing.
The Ligand deal strengthens Arecors financial position, supporting R&D priorities like AT278 and oral peptide delivery platforms.
The total addressable US insulin market for AT278 is estimated at $2.9 billion, with additional global commercialization potential.
These agreements mark significant milestones for Arecor, enhancing its pipeline, financial stability, and market opportunities in diabetes care.
AREC 08:31
Arecor Therapeutics PLC
Notice of Interim Results
AREC 06:01
Arecor Therapeutics PLC
Positive FDA Feedback on Phase 2 Study Design
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Arecor Therapeutics plc announced positive feedback from the U.S. Food and Drug Administration (FDA) on the Phase 2 clinical study design for its ultra-concentrated (500 U/mL) and ultra-rapid acting insulin, AT278, in combination with an Automated Insulin Delivery (AID) system. This first-of-its-kind study will evaluate AT278 in patients with type 1 and type 2 diabetes who have high daily insulin needs. Key highlights include
1. **Study Design Innovation**
Primary efficacy endpoint uses **Time-in-Range (TIR)**, enabling faster development compared to traditional HbA1c measurements.
Six-week dosing period for TIR vs. 12 weeks for HbA1c, accelerating clinical timelines.
Combination with an AID system to generate data on patient benefits and economic value.
2. **AT278’s Unique Features**
Only insulin in development with potential for longer wear in existing AID systems and future insulin pump miniaturization.
Ultra-concentrated and ultra-rapid profile addresses unmet needs in diabetes treatment.
3. **Phase 2 Study Details**
Planned IND submission to FDA in 2026, with study commencement in mid-2026, subject to funding.
Six-week cross-over study comparing AT278 (500 U/mL) with NovoLog® (100 U/mL) in <100 subjects.
Builds on positive Phase 1 data showing superiority over existing insulin products.
4. **Strategic Partnerships**
Arecor aims to partner with a U.S. insulin pump company for the Phase 2 study, advancing next-generation AID systems.
5. **CEO Commentary**
Sarah Howell highlighted the FDA feedback as a significant milestone, emphasizing AT278’s potential to simplify care and improve outcomes for diabetes patients.
Arecor is positioned to establish a new frontier in diabetes treatment, pending further financing and successful trial execution.
**END**

AI Crunch

Single-Ticker AI Crunch
AREC signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Arecor Therapeutics PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full AREC AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for AREC on 2025-09-29.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
25825516
Enterprise Value
61466548
Public Float
56.31
Broker Target
275.5
Shares Out
37756601
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BMWLM973
Market
None
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2025-09-18
Net Debt
-3007000.0
Cash
3239000.0
EPS
0.02
Net Income
-10236000.0
Revenue
5053000.0
Enterprise Value
61466548
Trailing PE
34.2
Forward PE
-
Price Sales TTM
5.1028
Price Book MRQ
8.527
EV Revenue
4.4734
EV EBITDA
-7.3253

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
7.014
Institutions As Of
2025-11-17
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
2
Sale Director Dealing
0
Purchase TR1
1
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit AREC.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-09-29 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Arecor Therapeutics PLC has fresh news flow feeding the chart narrative.
06:01 Today's Catalyst Directorate Changes
AI Charts Studio
AREC Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-09-29 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -9.51%
RSI Gauge
Price Change
AI Forecast